Two new funds, institutional backing and a pharmaceutical heavyweight give the European life sciences investor fresh capital to turn promising science into investable businesses.
Biotechnology has never suffered from a shortage of ambitious ideas. Financing them is another matter. Forbion has just supplied a €2.3 billion answer. The Netherlands-based life sciences investment firm announced on October 6, 2026, that it raised €2.3 billion, approximately $2.6 billion, across two new funds, its largest fundraising to date. The commitments bring assets under management to approximately €7.5 billion and provide capacity to finance roughly 30 biotechnology companies. The firm says its first investments from the new funds have already been completed. The bullish takeaway is not that every experimental medicine suddenly deserves a premium valuation. It is that sophisticated investors are committing substantial capital to a specialist capable of financing biotechnology from company formation through later-stage development. In a selective funding market, that represents a meaningful vote of confidence. BioPharma Dive described the fundraising as a potential lift for a European biotechnology industry that has fallen further behind its U.S. and Chinese counterparts. The laboratory lights are staying on. More importantly, someone has budgeted for what happens after the first encouraging experiment.
A Record Biotech Fundraising With Institutional Muscle
Forbion’s latest fundraising attracted existing and new investors, including Dutch pension investment organizations MN and PGGM, Germany’s KfW Capital, the Kauffman Foundation and Eli Lilly and Company (NYSE: LLY). The firm said demand substantially exceeded its target, although it did not disclose the original target or the allocation between the two funds. The participation of pension capital, an established foundation and a major pharmaceutical company gives the announcement weight beyond its headline number. These investors are backing a manager and its investment strategy, not certifying the success of every future drug candidate. Nevertheless, their willingness to commit capital supports a constructive interpretation: the opportunity to build valuable biotechnology businesses remains compelling even when financing conditions are demanding. Forbion’s managing partner and co-founder, Sander Slootweg, framed the raise as an opportunity to invest selectively in a market facing a general shortage of capital. That distinction matters. An indiscriminate funding boom rewards almost everyone for a while. A selective market can reward investors who know which scientific questions are worth paying to answer.
Two Funds Address Different Stages of the Biotech Journey
The new capital will flow through two complementary strategies. Forbion Growth Opportunities Fund IV focuses primarily on later-stage biopharmaceutical companies in Europe and North America developing novel therapies for significant medical needs. Forbion Ventures Fund VIII will invest in therapeutics-focused biotechnology companies, including existing businesses and new ventures built around promising assets and experienced teams. BioSpace reported additional detail from a Forbion spokesperson: the venture strategy will emphasize preclinical and early clinical-stage companies, while the growth strategy will provide private growth capital alongside selected crossover and public-market investments. The investment logic is straightforward. Early-stage companies need resources to establish whether their science can translate into credible medicines. More advanced businesses need financing to develop those programs further. Forbion’s two-fund structure positions it to participate at different points along that progression. For many watching biotechnology, the significance is the breadth of the financing toolkit. This is not simply a larger checkbook aimed at one narrow stage of development.
A Track Record That Extends Beyond Pitch Decks
Forbion reports that, over its 20-year history, it has financed 142 companies, including 37 that it helped create. Its portfolio companies have delivered 21 approved medical products benefiting more than 1.6 million patients globally. Those figures provide a useful counterweight to biotechnology’s familiar vocabulary of potential, platform and breakthrough. The firm is describing a history that includes company formation and approved products, not merely investments in promising presentations. Its current portfolio spans therapeutic companies targeting serious diseases as well as planetary-health businesses pursuing sustainable biotechnology and green chemistry. The two newly announced funds, however, focus on biopharmaceutical and therapeutic opportunities. The distinction keeps the investment story properly framed: Forbion has a broader biotechnology platform, but this €2.3 billion fundraising is principally about developing medicines. Historical achievements do not guarantee future investment returns. They do help explain why institutional investors might favor an experienced specialist when scientific ambition and financing discipline need to occupy the same room.
Gate Bioscience Shows How Scientific Platforms Can Attract Big Pharma
One recent example gives the broader investment thesis a tangible commercial connection. Forbion led Gate Bioscience’s $65 million Series B financing in November 2025, according to BioSpace. On October 5, 2026, Gate announced an expansion of its research and licensing collaboration with Eli Lilly and Company (NYSE: LLY), with potential agreement value exceeding $870 million, contingent on milestones. Gate is developing oral small-molecule medicines designed to eliminate certain disease-causing proteins at their source. Under the expanded arrangement, Gate leads discovery, while Lilly takes responsibility for later-stage preclinical and clinical development, manufacturing and commercialization. Lilly receives exclusive worldwide rights for products arising from the selected targets. For biotechnology investors, the relationship illustrates a potentially attractive division of labor: a specialist company develops differentiated science, while an established pharmaceutical partner supplies downstream development and commercial capabilities. The financial caveat is essential. The potential deal value is not an upfront cash payment. Gate’s economics include upfront and research payments, conditional milestones and potential royalties. The largest headline numbers depend on future achievements. Biotechnology dealmaking has many virtues. Turning every milestone into money already in the bank is not one of them.
Solstice Oncology Adds Another Concrete Investment Example
Forbion also participated in Solstice Oncology’s $225 million Series A financing, announced September 9, 2026, alongside lead investor RA Capital Management, Canaan Partners and other investors. The financing supports porustobart, an immuno-oncology therapy being developed for treatment before surgery, known as the neoadjuvant setting. Solstice’s program centers on a next-generation CTLA-4 antibody licensed from Harbour BioMed (HKEX: 02142), with development directed toward neoadjuvant Phase 2 testing in microsatellite-stable colon cancer. This illustrates the kind of opportunity a specialist biotechnology investor can help finance: a defined therapeutic asset, a specific clinical strategy and substantial capital committed to advancing development. The September transaction is evidence of Forbion’s recent investment activity, not a disclosed allocation from either newly raised fund. Keeping that distinction clear separates an informative investment narrative from an overly enthusiastic one.
What the Forbion Raise Means for Public-Market Investors
Forbion’s announcement is a private-fund capital raise, not a public-stock offering. The firm has not published a complete list of the approximately 30 companies that the new funds could finance. Its release says the first investments have been completed without identifying those allocations. For public-equity investors, the announcement is therefore more useful as a sector signal than as an immediate stock recommendation. Three implications stand out:
- Specialist biotechnology financing remains available at scale. Forbion’s record raise demonstrates that substantial institutional commitments can still flow to an established life sciences manager.
- Private science can create public-company opportunities. Gate’s relationship with Eli Lilly and Company (NYSE: LLY) shows how privately financed discovery platforms can become part of a listed pharmaceutical company’s development strategy.
- Investment selectivity remains central. Forbion’s stated focus is on promising companies addressing significant medical needs, not blanket exposure to the biotechnology sector.
The risks have not disappeared. Financing alone does not establish clinical efficacy, secure regulatory approval or guarantee commercial success. A pharmaceutical partnership also leaves considerable uncertainty when much of its potential value depends on future milestones, as Gate’s agreement demonstrates. The constructive interpretation is narrower and more credible: experienced investors are committing substantial resources to selected biotechnology opportunities, even while the broader financing environment remains challenging.
From Institutional Capital to a Bigger Stage for Healthcare Innovation
Forbion’s fundraising addresses one side of the healthcare investment equation: supplying the capital needed to advance promising medicines. Its two new funds reinforce the role of specialist investors in moving scientific opportunities toward meaningful development milestones. The other side is making the investment proposition understandable. A scientific thesis and an investment thesis are related, but they are not interchangeable. Investors must distinguish a compelling mechanism from a credible development plan, and a promising market from a commercially achievable opportunity. That provides a natural editorial bridge to Vista Partners’ “Four Days, Four Companies: A Bigger Stage for Healthcare Innovation.” Its title offers a complementary framing for the discussion: alongside institutional capital, healthcare innovation needs a stage on which investors can consider its possibilities and ask the difficult questions. The connection here is thematic, not a claim that the companies featured in the Vista Partners story are Forbion investments. The Forbion announcement concerns resources available to develop emerging medicines. The Vista Partners headline brings investor visibility into the conversation. Both perspectives belong in a thoughtful investment narrative. Funding gives a business the means to pursue its plans. Clear communication gives investors a framework for evaluating those plans. Neither should be confused with clinical evidence, operational execution or financial discipline.
Even the most elegant presentation cannot persuade a clinical endpoint to cooperate. Biology remains a notably independent member of the investment committee.
The Bull Case: Capital, Clarity and the Next Generation of Medicines
Forbion’s fundraising is compelling because it combines scale with specialization: approximately $2.6 billion in new commitments, complementary venture and growth strategies, institutional backing and a reported history of helping portfolio companies deliver approved medicines.[forbion]
Recent developments add substance to that broader story. Forbion-backed Gate Bioscience expanded its collaboration with Eli Lilly and Company (NYSE: LLY), while Solstice Oncology secured a $225 million financing with Forbion among its investors. These are distinct transactions, but both illustrate pathways through which specialist capital can support therapeutic development and commercial relationships.[biospace][finance.yahoo][finance.yahoo]
The healthcare investment conversation should not stop at the size of a fundraise. It should extend to the businesses, development strategies and investment questions that make innovation worth following. That is where the bigger-stage framing of the Vista Partners story fits into the narrative.
The bullish interpretation is not that biotechnology has become easy. It is that experienced investors see enough opportunity to commit serious capital while the market remains selective.[forbion][medcitynews]
Forbion has secured the resources to pursue its next generation of companies. The next test is what those companies deliver.
From Institutional Capital to a Bigger Stage for Healthcare Innovation at JPM 2027
Forbion’s fundraising addresses one side of the healthcare investment equation: supplying the capital needed to advance promising medicines. Its two new funds reinforce the role of specialist investors in moving scientific opportunities toward meaningful development milestones. The other side is making the investment proposition understandable. A scientific thesis and an investment thesis are related, but they are not interchangeable. Investors must distinguish a compelling mechanism from a credible development plan, and a promising market from a commercially achievable opportunity. Alongside institutional capital, healthcare innovation needs a stage on which investors can consider its possibilities and ask the difficult questions.Vista Partners’ sister company, Tribe Public (www.TribePublic.com), is expanding its CEO Presentation & Q&A Luncheon series during the annual J.P. Morgan Healthcare Conference, hosting four corporate-sponsored, RSVP-only events January 11-14, doubling its traditional two-event schedule. Taking place daily from noon to 2 p.m., each luncheon is expected to welcome 50–80 attendees from the dedicated Tribe Public community. One company will take center stage each day, giving its CEO a focused opportunity to share the company’s vision, highlight its latest developments and growth opportunities, and engage directly with attendees through a live Q&A. For participating companies, this expanded series offers a compelling platform to elevate visibility, build relationships, and bring their stories to an engaged audience during a major week for healthcare.
A Global Community. A Collective Voice. Direct Access.
Tribe Public aggregates the voices of consumers and investors to attract management teams from some of the world’s most interesting and groundbreaking companies to its corporate-sponsored, RSVP-only CEO presentations, Q&A luncheons, dinners, speaking engagements, and webinars. This growing community now spans 31 countries and is accessed via its ongoing Tribe Public CEO Presentation and Q&A Webinar based event series. Tribe Public also hosts luncheon, dinner, and speaking engagement events across 41 Tribe Event Venues in the United States. Members regularly learn alongside one another and engage directly with company leadership and experts. The Tribe Public audience includes portfolio managers from large and small funds, registered investment advisors, family offices, accredited investors, business owners, retail traders, brokers, sell-side analysts, entrepreneurs, and members of the media. This diverse community brings thoughtful questions and a broad range of perspectives to every conversation.
Capital-Markets Expertise. An Integrated Communications Platform.
Vista Partners LLC is a California-registered investment advisor with capital-markets and strategic-advisory capabilities. Its focus complements the opportunity for companies to communicate their vision, articulate their growth strategies, and build meaningful relationships with the investment community. Vista is led by its Managing Member, John F. Heerdink, Jr, an advisor, investor and entrepreneur, who has advised public and private companies across all sectors with an emphasis on biotechnology, healthcare, technology & natural resource companies. In addition, Mr. Heerdink has worked with companies seeking a listing on public exchanges via IPO, reverse merger and assisted foreign issuers seeking a listing on a U.S. exchange. Mr. Heerdink has assisted companies to raise debt and equity capital for growth, consummated mergers and acquisitions, and performed all other matters dealing with investor relations, business development, & marketing. He maintains an extensive relationship base in the investment community, lending industry, investment banking industry & a worldwide investor network. Learn more about Vista Partners: www.vistapglobal.com/about-vista-partners/.
Tribe Public LLC is an integrated media, communications, and investor-event platform that supports live experiences, digital events, original content development, social distribution, and targeted outreach. These capabilities create opportunities to extend company storytelling beyond a single presentation and support continued audience engagement. Learn more about Tribe Public: www.TribePublic.com.
Inquire Now
With an expanded four-day luncheon series and a growing global community, Tribe Public is creating more opportunities for healthcare leaders to tell their stories, and for investors and consumers to hear directly from the people shaping what comes next. if you would care to join these upcoming events, then please join the Tribe by registering at www.TribePublic.com and/or send a message to Events@TribePublic.com. If you are a company CEO or Director of Investor Relations that would like to learn more and/or to be considered to be a presenter during the J.P Morgan Healthcare Week in San Francisco or otherwise across the U.S., then please send a request to Research@TribePublic.com.
The Sources
- Forbion: “Forbion Raises €2.3 Billion Across Two New Funds”
https://forbion.com/news-insights/news/forbion-raises-23-billion-across-two-new-funds/ - Forbion: Current Portfolio Companies
https://forbion.com/portfolio/?status=Current - BioPharma Dive: “Forbion, a Prominent Biotech Investor, Raises $2.6B for a Pair of Venture Funds”
https://www.biopharmadive.com/news/forbion-venture-capital-growth-fund-fundraise/832254/ - BioSpace: “Biotech VC Forbion Raises Record $2.6B to Support 30 ‘High-Potential’ Companies”
https://www.biospace.com/business/biotech-vc-forbion-raises-record-2-6b-to-support-30-high-potential-companies - Tech Funding News: “Eli Lilly, PGGM and KfW Capital Back Forbion’s €2.3B Fund for 30 Biotechs”
https://techfundingnews.com/eli-lilly-pggm-and-kfw-capital-back-forbions-e2-3b-fund-for-30-biotechs/ - STAT: “Forbion Raises $2.6 Billion, Its Largest Fundraise to Date”
https://www.statnews.com/2026/10/07/biotech-news-forbion-raises-2-6-billion-largest-fundraise/ - MedCity News: “Forbion Bucks VC Fundraising Trends, Reeling In €2.3B for Biotech Investing”
https://medcitynews.com/2026/10/forbion-venture-capital-life-sciences-biotech-startups-investing-vc/ - Gate Bioscience, via Yahoo Finance: “Gate Bioscience Expands Collaboration and License Agreement With Lilly”
https://finance.yahoo.com/healthcare/articles/gate-bioscience-expands-collaboration-license-120000949.html - Reuters, via Yahoo Finance: “Gate Bioscience Expands Lilly Drug Discovery Deal Worth More Than $870 Million”
https://finance.yahoo.com/healthcare/articles/gate-bioscience-expands-lilly-drug-123507929.html - Solstice Oncology, via Yahoo Finance: “Solstice Oncology Launches With $225 Million Series A Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology Therapy”
https://finance.yahoo.com/healthcare/articles/solstice-oncology-launches-225-million-110000487.html - BioPharm International: “Solstice Oncology Launches With $225M to Advance Next-Generation CTLA-4 Antibody Porustobart”
https://www.biopharminternational.com/view/solstice-oncology-launches-with-225m-to-advance-next-generation-ctla-4-antibody-porustobart - Harbour BioMed, via Morningstar: “Harbour BioMed Partner, Solstice Oncology, Announces $225 Million Series A Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology Therapy”
https://www.morningstar.com/news/pr-newswire/20260909cn43400/harbour-biomed-partner-solstice-oncology-announces-225-million-series-a-financing-to-advance-porustobart-a-neoadjuvant-immuno-oncology-therapy - Vista Partners: “Four Days, Four Companies: A Bigger Stage for Healthcare Innovation”
https://vistapglobal.com/four-days-four-companies-a-bigger-stage-for-healthcare-innovation/
Stay Updated with Vista Partners
Subscribe to receive market insights, investing ideas, and the latest updates directly in your inbox.
